Narrative based medicine is not the opposite of evidence based medicine: rather it's an essential accompaniment.' Richard Smith, Editor, BMJ 2 January 1999 Summary: Our understanding of genitourinary chlamydial infection and disease remains limited. That natural defences and/or apparently adequate treatments leave some patients with latent disease is suspected. There is, however, no consensus as to its nature. Furthermore, many patients, most obviously males, presenting with similar or identical symptoms and signs remain unexplained in microbiological terms; this in spite of many years of dedicated research endeavour. The recent trend towards an impasse has coincided with a growing acquaintance with the immunobiology and immunopathology of chlamydial infections. The time would seem to have arrived for a reappraisal of available clinical and laboratory observations.
INTRODUCTION
Harkness in 1950 1 was the ® rst to report the ® nding of epithelial cell`inclusions' in urethral smears, from men with non-gonococcal urethritis (NGU). He saw these as akin to the`big viruses' associated with lymphogranuloma venereum (LGV) and psittacosis and soon to be found in trachoma. These`big viruses' were eventually to be called Chlamydiae.
The Chlamydia trachomatis of genitourinary infections was discovered in 1964 by Dunlop' s group in London 2 . Since then microbiological research has followed 2 lines. Firstly, tests for isolating the organism and identifying its serovars have been followed by a series of consistently more successful tests capable of identifying the various forms of the relevant Chlamydiae and their antigenic components, intermediate forms or remnants. Culture diagnosis was initially replaced in routine clinical practice by enzyme immunoassay (EIA) and/or microscopic identi® cation of the organism using monoclonal antibodies. More recently, the more sensitive molecular diagnostic techniques, such as polymerase chain reaction (PCR), ligase chain reaction (LCR) 3 , and transcription-mediated ampli-® cation (TMA) 4 have been introduced as the neẁ gold standard'. Diagnostic levels have improved and reliable tests can now be performed on urine and self-taken genital swabs.
The second line of research has sought to ® nd a second common causative organism. Such endeavours were encouraged by Bowie's World Health Organization (WHO) report in 1978 5 . In spite of many years of devotion to this line, Ureaplasma urealyticum and Mycoplasma genitalium are judged causal in only a small minority of cases. With so many NGU cases unexplained, a sense of impasse has grown.
In 1993, the many unanswered questions were listed and some tentative research suggestions made 6 . This was followed in 1994 in the USA 7 and in 1995 in the UK 8 by detailed updates regarding the known immunobiology and immunopathology of chlamydial infection. The conclusion of these 3 papers is perhaps best summarized by Beatty et al. 7 .`Components of the immune system nutrients, hormones and other infectious organisms, alone or in concert, may alter the chlamydia± host± cell relationship resulting in persistent (latent) chlamydial development. Chlamydial persistence awaits identi® cation.'
What follows is an attempt to meet this challenge.
TO BEGIN AT THE BEGINNING
It is increasingly recognized that many patients, when screened routinely or as sex contacts, have chlamydia-positive tests but present neither symptoms nor signs of genitourinary disease. This carrier state is more readily recognizable in males. To date it has been unidenti® ed and ignored as a separate diagnosis. That innate immune responses may have a modest success rate in eliminating both carrier state and infection is suggested by the declining percentage of positive chlamydia tests with increasing age. Clay and Bowman, in a study of 1042 females, found 21.1% positives in 15± 19- year-olds dropping to 2.8% in women aged 30± 39 9 .
What do innate immune responses consist of in the presence of C. trachomatis in the genitourinary system? Vaginal secretions have anti-chlamydial activity when applied to McCoy cell cultures. Innate responses to genital chlamydial infection may vary during the menstrual cycle and be in¯uenced by oral contraceptives. Presumably Do È derlein's bacilli, if available, will produce either lactic acid or hydrogen peroxide. Mucus may contribute. Post-prandial alkalinization of the urine provides recognized phosphate`inhibitors' of chlamydiae. If present, C. dif® cile secretes a creosol-like substance 10 . Nitric acid secreted by infected epithelial cells inhibits intracellular multiplication of the organism 11 . More recently, fatty acids and monoglycerides 12 , some occurring in breast milk, were found to be chlamydiacidal agents which disrupted cell membranes of elementary bodies (EB).
Inherent in the diagnosis of carrier state in males is that urethral smear cell counts are within wellrecognized normal limits. In contrast to the quantitative we have little knowledge of whether or not there is qualitative change in the proportion of white cell types. The respective contributions of cellular and humoral immunity in the carrier state is unknown. In what proportion of carriers overt disease supervenes is also unknown.
Clinicians would ® nd it helpful in their struggle to distinguish between cases of relapse and reinfection if identi® cation of causative chlamydial types in carriers and so-called ® rst overt infections could be separately identi® ed.
THE SO-CALLED FIRST INFECTIONS
So-called ® rst attacks of NGU in men are manifest clinically by anything from profuse purulent urethral discharge to as little as an excess number of white cells in urethral smears. The corresponding condition in females is some degree of endocervicitis with variable muco-purulent discharge. Some may be urethral carriers or have urethritis. Proctitis may occasionally be found in both sexes. Females with early disease are more often symptomless. In both sexes the conditions described are generally labelled`uncomplicated' although which complications have been excluded, and how, is not mentioned. For example, is posterior urethral involvement in men a complication? Tests as well as clinical observations to eliminate Neisseria gonorrhoeae, Trichomonas vaginalis infestation and bacterial cystitis are essential preludes to tests for chlamydial infection. Positive tests for C. trachomatis occur in up to 70% of cases of early disease. When left untreated, 32% of men with chlamydia-positive urethritis have chlamydianegative discharge within 45 days 13 .
PATHOGENESIS OF CHLAMYDIAL INFECTION
The pathogenesis of early chlamydial disease begins with serial infection of surface epithelial cells ( Figure 1 ). This is effected by receptormediated endocytosis. Once inside the cell, chlamydiae are contained within host-derived endosomes. These coalesce within a cytoplasmic vacuole thus evading the threat of lysosome activity. By utilizing cellular material, the ingested EB undergo reorganization into reticulate bodies (RB). These undergo binary ® ssion and maturation to be released as EB on natural death of the epithelial cell. For slow growing genital D± K strains, which are predominantly luminal pathogens, the development cycle takes 48± 72 h.
Dying epithelial cells release cytokines 14 which promote increased blood supply with increased permeability of basal membranes which allows migration of lymph node cells. These enter local tissues by diapedesis from venules. Table 1 shows the distinctive differential white cell count associated with urethral exudates associated with NGU in men 15 .
At the same time, the causative chlamydia travel by lymphatics to the relevant lymph nodes. In cases where the epithelium of the fossa navicularis and perimeatal areas is involved, an enlarged inguinal lymph gland may be palpable. Study of needle puncture material in such cases by one of us (GRK) has revealed C. trachomatis by culture. Detailed histological studies of such glands should be considered.
Some EB freed by dying epithelial cells are completely phagocytosed by neutrophils. Antigenactivated T-lymphocytes undertake a variety of defence roles including phagocytosis and production of gamma interferon (IFN-g). Studies in mice have shown that IFN-g production by cytotoxic CD8 T-lymphocytes is required for resolution of infection 16 . IFN-g also enhances the ability of other phagocytes, particularly monocytes and macrophages, to ingest chlamydiae. The role of monocytes and macrophages in terms of complete phagocytosis and chlamydia killing is less clear. IFN-g may also play a role in persistence of C. trachomatis. Laboratory experiments suggest that variations in its concentration prompt both persistence and reactivation in cultures 32 .
In addition to these primary cellular responses, there are also a variety of molecular and humoral responses. During their replication, chlamydia may have their antigens introduced into major histocompatibility complex (MHC) class 1 processing pathways, present in almost all cell types, leading to the activation of CD8 lymphocytes. The major outer membrane proteins (MOMP) are the major target both for neutralizing antibodies, which appear to be of limited ef® cacy, and for protective T-cell responses. In non-professional phagocytes, there is no expression of MHC class 2 molecules, hence infected cells remain unrecognized by CD4 lymphocytes. Nevertheless, IL-4 from T-lymphocytes will activate macrophages and promote their antibacterial actions. This TH1 cell-mediated im-mune response is characteristic of all cellular responses to late chlamydial infections.
Epithelial infection by chlamydia is associated with up-regulation and secretion of pro-in¯ammatory cytokines such as interleukin (IL)-8, growth related protein (GRO), granulocyte/macrophage colony stimulating factor (GM-CSF), and IL-6. In contrast to the rapid cytokine induction caused by extracellular bacteria, the epithelial cytokine response associated with C. trachomatis is delayed for 20± 24 h after infection, requires bacterial protein synthesis, and persists throughout its growth cycle. Chlamydial lipopolysaccharide (LPS), associated with the bacterial plasma membrane, induces IL-1 release from monocytes and macrophages, which in turn induces the release of tumour necrosis factor, a potent initiator of the in¯ammatory process. Lysis of epithelial cells is also associated with IL-1 release and stimulates adjacent non-infected epithelial cells to produce additional cytokines. These cytokines are potent chemoattractants and activators for neutrophils, monocytes, and T-lymphocytes. Neutrophils are capable of killing chlamydia by fusion of their lysosomes with ingested elementary bodies. Other cytokines have pleiotropic effects including the induction of adhesion molecules on endothelial cells, secretion of cytokines by macrophages and of acute phase proteins in epithelial cells and macrophages. Nevertheless, because invasion of host cells is usually silent and host cell lysis is relatively slow, this minimizes the clinical manifestations of the in¯ammatory response.
Studies in trachoma suggest that variations in ability to clear chlamydia may depend on the severity of the chlamydia load and its duration 17 . T-cell responses are depressed and inadequate in those with persistent trachoma as compared with those recovering from the infection, whilst humoral responses may be accentuated. Whether the same also applies to genital infection is unknown. The dynamics of cellular responses requires further clari® cation. That cellular responses continue after apparent eradication of chlamydiae also calls for explanation.
TREATMENT OF EARLY UNCOMPLICATED INFECTION
In the 1950s, the idea that NGU was caused by à big virus' was supported by the condition's response to a variety of antibacterials. Parallel responses were noted in the treatment of lymphogranuloma, psittacosis and trachoma, also in laboratory mice when the causative organisms of these 3 infections were used to induce peritonitis. While tetracycline gave the best results in the conditions listed, it was associated with the highest recurrence rates in both clinical and laboratory circumstances 18± 20 . It is now recognized that alongside its antibiotic action, tetracycline has the potential for immunosuppression. When the ef®ciency of other antibiotics was measured in terms of recurrence rates at 3 months' follow up, they were found to have the same ranking in both humans and laboratory-infected mice 18, 19 . Tetracyclines alone or in combinations, in courses of a week, were popular from the 1960s. Recently, azithromycin in a single oral dose has proved to be increasingly favoured in carriers and iǹ uncomplicated' early overt disease whether chlamydia positive or negative. Figure 1 shows the life cycle site [T] at which the tetracyclines and azithromycin are said to operate effectively. Penicillin, said to operate at the site marked [P], interferes at a critical point in the transformation of RB to EB, and induces abnormal inclusions with consequent release of heat shock proteins (HSP60). These in turn activate dendritic cells and prompt immunological responses. Penicillin treatment is not only less effective, but is more frequently followed by Reiter's syndrome 21, 22 . Matzinger's`danger model' theory seems to offer the best explanation for this phenomenon. Infected cells when dying unnaturally are viewed as being liable to leak dangerous materials and the damage these cause prompts immune responses 23, 24 .
With an intracellular life in epithelial cells of some 72 h, it would be of interest to learn the percentage of chlamydiae killed by intracellular concentrations of the various antibiotics and the percentage killed extracellularly by serum concentrations. Do time/dosage relationships match the intracellular life cycle? It is notable that the organism completes its life cycle in a vacuole within each infected epithelial cell apparently free of and immune to a multiplicity of cellular and molecular activities. Whether antibiotics enter vacuoles and have more success, is not known. This seems unlikely. It is more likely that antibiotics operate when cells die naturally.
Extracellular concentrations of some 14 antibiotics have been compared with the concomitant intracellular concentrations as they concern macrophages 25 . Ratios varied widely being lowest in the case of penicillin and highest with erythromycin and clindamycin. It is known that some pathogens are capable of living in macrophages, for example, Mycobacterium tuberculosis, HIV, listeria, salmonella and Staphylococcus aureus. Known intracellular antibiotic concentrations do not alter this symbiosis. Only one exception has been found. Rifampicin, being more lipid soluble, achieves an intraalveolar macrophage concentration twice that obtained extracellularly and is apparently active against intra-alveolar-macrophage tubercle bacilli. It has also been shown that C. pneumoniae strains recovered from arteriosclerotic coronary arteries share the same antimicrobial patterns of susceptibility as those found in acute respiratory infections with macrolide antibiotics and rifampicin being the most active drugs 26 .
Research is needed to de® ne if antibiotics entering cells kill chlamydiae or if their chlamydiacidal activity is con® ned to EB released when infected cells die naturally. Such pharmacokinetic studies may hold the clue to our ability to unravel suspected latency and the need for more ef® cient or longer duration therapy. There is no doubt that azithromycin and roxithromycin enter cells, especially macrophages, in high concentrations but to date there is no proof that they are any more effective intracellularly than other antibiotics or immune responses.
DEFINING CURE
Until the present decade, cure of NGU and its counterpart, endocervicitis, was de® ned by posttreatment absence of symptoms and signs, maintained during a 3-month follow-up period. Posttreatment laboratory tests were only occasionally used. More recently, tests used for diagnosis of chlamydial infection have been deployed at 4 weeks post-treatment. Negative results have led to declarations of`eradication' of chlamydiae. While this may well be true in the case of carriers, the history of treatments in cases of overt early disease over the last few decades makes the claim questionable. These different clinical states Ð carrier and disease Ð call for closer, separate and comparative study.
RECURRENCES
Recurrences have long been recognized as common in all forms of chlamydial infection in both humans and laboratory animals. In lymphogranuloma recurrences, the L1, 2 or 3 serovars can usually be identi® ed again and supported by rising titres in complement ® xation tests. By contrast, the serovars A, B, B1 and C are rarely found in recurrences of clinical trachoma. It is otherwise in clinically persistent cases of trachoma. Recently, 19 of 24 episodes of chlamydia pneumonia were labelled recurrences 27 . In the case of psittacosis, it is not uncommon to ® nd continuing excretion of the causative chlamydiae in clinically-cured humans and birds.
A joint Swedish and British group studied the role of B-lymphocyte subsets in response to chlamydial antigens. It was found that female mice, made genetically de® cient of B-cells, were capable of clearing a primary ascending chlamydial infection equally as fast or faster than wild-type mice. Both groups of mice demonstrated immune protection. High titres of chlamydia-speci® c antibodies were found locally and systemically only in the wild-type mice. It was concluded that cellmediated responses, particularly the presence of CD4+ cells and T1 helper cells, play a critical role in the defences against chlamydiae. A follow-up study revealed that this protection required the presence of T1 helper cells producing IFN-g. The authors posed the question`Is this true for humans also?'. The answer was sought through a study of 94 Gambians with trachoma. Using an enzymelinked immunospot assay of antibody secreting B cells against MOMP and HSP60, chlamydia-speci® c IgA suppression was detected in cases of intense trachoma'. This de® ciency, the authors suggest, may play a role in the continuing tissue damage and scarring.
Using the 3 months clinically-based routine of follow-up in the 1950s to 1980s, men treated for NGU had a recurrence rate above 15%. Of 221 followed up for a year, Munday found 45 (20%) with recurrence 28 . A 3-year follow-up routine applied to females showed a 38% recurrence rate 29 . Little wonder that one clinician who followed up cases for 5 years declared`Treatment helps Ð but not much' (Fowler, personal communication).
In the last decade, follow-up after single dose treatment with azithromycin has been by laboratory testing 4 weeks after therapy. One study found positive PCR results in 5 (5.1%) of 98 women treated with a single dose of azithromycin 30 . Of 98 women treated with a 7-day course of doxycycline, 4 (4.1%) were positive. All those found positive had`behavioural risk factors' suggesting re-infection. Only one study has been found where, after a single dose of azithromycin, male patients were followed up clinically for 3 months. The recurrence rate was then 12% 31 .
Laboratory experiments suggest that variations in INF-g concentrations may induce persistence and/or reactivation of chlamydial cultures 32 .
Attempts to minimize recurrences in humans have been only partially successful. Recurrences occur in LGV and trachoma even after repeated or extended courses of treatment. In NGU, a trial of triple tetracycline given for one week was compared with a regimen lasting 3 weeks. Post-treatment follow-up for 3 months showed the clinical recurrence rate as halved 33 . Hurst et al. treated mice infected peritoneally with LGV, psittacosis and trachoma chlamydiae, for over 200 consecutive days. This eliminated recurrences but not the disease which he found at postmortem in spleens and livers 19, 20, 34 . Little wonder then that some clinicians suspect that apparently`adequate' treatment does not`eradicate' the complete chlamydia load in humans. This is a feature wellrecognized in`adequately treated' early syphilis where pathogenic Treponema pallidum can be recovered from lymph nodes.
Progress may be hastened by new molecular methods of monitoring chlamydial infections after treatment. Detection of the 16S ribosomal RNA (rRNA) chlamydial component by nucleic acid sequence based ampli® cation has been employed in a preliminary study using cervical smear and urine specimens 35 .
THE NATURE OF RECURRENCE
Only in the case of genitourinary chlamydial disease has there been serious discussion as to whether recurrences are re-infections rather than relapses. That recurrences of NGU are more likely to be relapses is supported by a variety of clinical observations. Firstly, the contrasting sexual histories given by men with recurrences of gonorrhoea and those with recurrence of NGU, as, for example, detailed by Evans 36 . Secondly, the ® ndings re prevention of recurrences in animals and men as noted above, and thirdly, 4 studies out of 6 have shown that treatment of their sex partners does not in¯uence recurrence rates in men 37± 42 .
A persistent and striking feature of recurrences of NGU is that yields of positive diagnostic tests for C. trachomatis are usually only half those found in initial attacks of NGU, for example, 35% and 70%. Shahmanesh et al. in 1996 43 reported the accompanying cellular details. They compared lymphocyte counts in ® rst and recurrent attacks of chlamydia-positive and chlamydia-negative cases of NGU. The lowest lymphocyte counts were in chlamydia-negative recurrences. These ® ndings were supported by total in¯ammatory cell counts of ® rst-voided urine samples (see also Table 1 ). On discussing their observations, the authors concluded that their ® ndings tended to support a separate non-chlamydial aetiology.
Could there be another explanation? It is a wellestablished immunological truism that re-infection with an organism previously subjected to a primary immune response is more assertively, more speedily and hence more effectively dealt with by a secondary immune response. During re-infection or reactivation, the in® ltration of T-lymphocytes occurs more rapidly and in larger numbers.
The establishment of memory cells and both helper and killer cells occurs as part of the primary immune response. Is it not possible that the ® nding of fewer lymphocytes in urethral exudates in chlamydia-negative recurrences is the result of ef® cient secondary immune responses? Is it possible that the diagnostic dif® culties in recurrences, attributed by some to reduced expression of chlamydial antigens, can really be an acceptable measure of nature's success? This questions whether the secondary immune responses only apply to individual serovars or to all strains causing genital infection. Studies directed at identifying causative D± K types, both serologically and genotypically, in ® rst and subsequent attacks and aligning these with patients' histories of exposure are clearly indicated.
Does it matter whether recurrences originate exogenously or endogenously? Are both not reinfection of susceptible epithelium? This question is prompted by the observation that positive laboratory tests for C. trachomatis are commoner in cases of gonorrhoea than in cases of NGU. Why is this? Time was when cured gonorrhoea was occasionally followed within a few days by post-gonococcal NGU. This was clinically acceptable; it re¯ected the differing incubation periods. Today, however, tests for gonococci and C. trachomatis are carried out at initial attendances and commonly both are found positive. Presumably some cases have been chlamydia carriers and others recently infected. Could there be a third form? Is it possible that the gonococcus unmasks latent infection and so produces recurrence? We know that gonorrhoea and NGU can reveal asymptomatic HIV infection in which some 80% of the total viral load exists in lymphatic tissues 44, 45 .
Clearly, all recurrences of NGU call for more detailed study. There is need to try and resolve the relapse/re-infection controversy. One starting point would be to study the recurrence rates in infected carriers and in those with early disease. De® ning the distribution of serovars D± K in an area and identifying the serovars in initial partnerships and in those associated with recurrences might be helpful. Recent advances in genotyping of C. trachomatis by restriction fragment length polymorphism of omp 1 gene offer more discriminatory power and is more convenient than serotyping 46 . Genotyping has been employed in a study correlating patient characteristics and clinical manifestations of infection 47 .
Is there still a place for the 3-month clinical followup routine to help resolve disparate laboratory and clinical ® ndings? If support for the idea that recurrences originate in lymph nodes is a possibility, then there is need to exclude the existence of canalicular spread as part of the follow-up.
The terms`eradication' and`uncomplicated' need reconsideration. Meantime can we learn anything from a review of early complications?
COMPLICATED EARLY DISEASE
Contiguous spread in men consists, ® rstly, of posterior urethral involvement. Prostatitis may follow and be evidenced by an excess number of pus cells in expressed prostatic¯uid or in semen 48 .
Only recently have C. trachomatis remnants been found in prostatic secretion and then only in 4 of 135 cases of chronic prostatitis 49 . In acute epididymitis, especially in those men aged under 35, a chlamydial cause should be considered. Examination of aspirates can con® rm suspicions. In contrast to salpingitis, epididymitis is usually unilateral. Its resultant scarring is palpable for life.
Between 1 and 2% of men with NGU develop Reiter's syndrome. It is commonly acute with a tendency to recur. Fluid from affected joints and/ or specimens of synovia, from cases of conjunctivitis and skin manifestations of Reiter's syndrome have all revealed C. trachomatis or its antigenic remnants 50, 51 .
Most early complications in women arise by direct canalicular spread. As many as 10% may be affected by endometritis followed by acute, subacute or chronic surreptitious salpingitis. Recurrence of acute and subacute pelvic complications are common as are subsequent ectopic pregnancies and infertility. The microbiological basis of recurrent pelvic in¯ammatory disease (PID) raises questions. Responses to therapy are said to be best when an antibiotic is supplemented by metronidazole which acts against a variety of facultative pathogens, especially anaerobes. Could such situations be a parallel to the suggested unmasking of chlamydial infection by the gonococcus? Striking parallels occur in community-acquired pneumonias 37, 52 . Dual infections, with C. pneumoniae the common feature, give a situation commonly requiring more than one antibiotic. Again, the suggestion that other organisms may unmask latent chlamydial infection demands consideration.
Another early complication is the Fitz-Hugh± Curtis syndrome 53± 55 . It consists of acute-peritonitis and perihepatitis with some degree of ascites. It can occur without evidence of pelvic disease. That acute peritonitis in humans may be due to C. trachomatis was clearly con® rmed by Shanahan in 1990 . He cultured the organism from peritoneal exudates and imitated Hurst's work by using the cultures to give mice peritonitis. Both humans and mice were subsequently`cured' without surgery, that is, by antibiotics alone. Like Hurst's mice, Shanahan found the causative chlamydiae in the spleens of both his`cured' mice and`cured' humans at follow-up 56 . Recently, tissue specimens from similar cases gave positive results by RT-PCR (Adrian Eley, Microbiology Department, Shef® eld University, personal communication).
THE NATURE OF PERSISTENT/LATENT INFECTION
Latent infection may declare itself, apparently spontaneously, in the form of muted complications. For example, Reiter's syndrome may present as `idiopathic iritis'. Such cases rarely have a past or present history of urethritis although a few may have had`cystitis'. Chronic prostatitis and/or sacro-iliitis is found in over half the cases 48, 57 . Mild forms of PID may present as pelvic pain, menorrhagia or intermittent low backache. The irreversible sequelae of all forms of PID were reviewed in detail by Paavonnen in 1996 58 . Positive serological tests in PID with recurrences has not, to date, been highly regarded. Recently, specimens from fallopian tubes, the endometrium or ovarian biopsies have revealed functional C. trachomatis DNA by PCR. The`excellent correlation' has been con® rmed using a chlamydia antibody test at the UK Public Health Laboratory Service STD Centre (O. Caul, personal communication). Such work calls for encouragement in the hope that serological responses may play as useful a role in C. trachomatis (D± K serovars) infection as they do in C. pneumoniae infections 27, 52 .
From what has been said, the spleen and the lymphatic system appears to be the most likely location for latent chlamydial infection. An historical perspective offers support. Reiter's original paper in 1916 described his syndrome in Finnish soldiers with bacillary dysentery 59 . Fiessinger and Leroy, some months later, reported the same phenomenon in French soldiers on the Somme 60 .
(RSM saw his ® rst case of Reiter's syndrome in a British soldier in North Africa in 1942 while involved in the early trials of sulphaguanidine in bacillary dysentery.) The organisms causing bacillary dysentery make exceptionally heavy demands on the lymphatic system especially the pelvic and pre-aortic nodes. These also serve much of the genitourinary system most notably in those with canalicular spread. We suggest that lymph nodelodged chlamydiae may accompany the¯ood of phagocytes hastening to defend the bowel. The concomitant chlamydiae`bacteraemia' would then account for the widespread nature of the syndrome's manifestations. Again, we contend, overt chlamydial disease follows unmasking of lymphnode latency.
This view is supported by observations in lymphogranuloma venereum where, following an evanescent genital lesion, chlamydiae are concentrated in the lymph glands. No one has questioned that these are the origin of the multiple arthritis and ® ndings of LGV serovars in the central nervous system (CNS) which occasionally complicate this infection.
Latency in the lymphatic system is therefore not only a possible explanation for generalized early complications but also for unheralded recurrences of PID and Reiter's syndrome as well as the diverse late complications.
If, as suggested, latency is centred in the spleen and lymphatic system, how does that system hold the C. trachomatis in a state of suspended animation for months or years? How does C. trachomatis remain capable of pathological activity? Thirdly, what facility has the lymphatic system to transport chlamydia serovars D± K, and precipitate foci of infection in genitourinary epithelium and/or in the varied sites associated with Reiter's and Fitz-Hugh± Curtis syndromes?
The cell-mediated responses in terms of both primary and secondary immune responses as described by Shahmanesh et al. appear worthy of closer scrutiny especially the dominant role they accorded to macrophages. Macrophages are descendants of monocytes in which chlamydiae can be harboured for up to 10 days. With a normal life span of one month or more, macrophages circulate freely some taking up residence in lymph nodes, others in spleen, the lungs and/or serous cavities from where they may recirculate. They are attracted to sites of in¯ammation. They are abundant in all forms of NGU and have long been recognized as persisting in the inguinal and pelvic glands of LGV 61 . Their presence in abundance has recently been noted in C. pneumoniae infections 62 . The LPS of C. pneumoniae induces human macrophage foam cell formation, a key event in early atheroma formation 63, 64 .
Interferon-gamma derived from CD4 and CD8 lymphocytes is believed to mediate persistent chlamydial infection in macrophages. Laboratory experiments suggest that variations in INF-g concentration may induce persistence and reactivation of chlamydia cultures 32 . Such cytokine activity appears to strike a balance so that intracellular killing is incomplete and antigenic material lives and is passed on to succeeding generations of macrophages. This phenomenon is recognized as operational in trypanosomiasis 65 , and, more recently, in tuberculosis 66 .
In experimental infection of cultured human blood monocytes with serotype K, persistent, non-productive infection by chlamydiae contained in aberrant cytoplasmic inclusions also occurs although primary chlamydial rRNA transcripts, indicative of viable, metabolically active infection have been demonstrated. In vitro studies have also demonstrated IFN-g induced persistent chlamydial infection with macrophages, mediated, at least in part, by the induction of indoleamine 2,3 hydrogenase which limits the supply of tryptophan and causes iron deprivation. Persistently infected macrophages contain characteristic enlarged, abnormal RB ultrastructurally similar to those induced by nutrient depletion and the action of penicillin-based antibiotics. There is a paucity of outer membrane constituents, such as MOMP and LPS. Nevertheless, levels of heat shock proteins, which promote intracellular survival, are maintained.
We suggest that the proven diverse capacities of macrophages make only a limited contribution to the elimination and control of chlamydial infection. The state of persistent infection which they display allows reactivation and early disease recurrences.
One more test remains. Does this suggestion ® nd support in the history and clinical manifestations of late overt chlamydial disease?
LATE OVERT DISEASE
The course in all late forms is usually surreptitious, sometimes punctuated by episodes of overt activity. Late infected sites, particularly in the female pelvis and Reiter's arthropathy produce a common histology. It manifests leucocytes, lymphoid follicles, plasma cell in® ltration, ® broblasts and macrophages.
The mode of parasitism suggested can be seen as a possible basis for late overt disease. Macrophages in their wanderings have been shown to have an af® nity for sites of in¯ammation. A comparatively low, continuous or intermittent¯ow of infested macrophage dying at genitourinary or peripheral foci could therefore prompt and continuously maintain the immunological responses.
Chlamydia heat shock protein 60 (Chsp60) is important in immunopathology with well-documented associations with PID, ectopic pregnancy, tubal infertility, and trachoma. Risk factors for antibodies to Chsp60 include older age and repeated infection. Whether or not antibody to Chsp60 is causally involved in the immunopathogenesis of the longterm sequelae or is merely a marker of persistent chlamydial infections remains controversial. There appears to be some genetic restrictions for these antibody responses. Recently, antibodies to Chsp60 peptide 260± 271 homologous to human hsp60 have been shown in women with laparascopically veri® ed PID 67 . This indicates that an autoimmune response to human hsp60 can develop in some infected patients probably as a consequence of an immune response to a Chsp60 epitope crossreactive with human hsp60. It is likely that there are other host genetic variants which in¯uence the clinical response to chlamydial infections. HLA B27 has long been associated with Reiter's syndrome and the class I allele HLA-A31 has been associated with chlamydial PID.
These cellular responses are generally described as delayed hypersensitivity. In terms of clearing antigenic material, these responses appear to be more effective than secondary responses. But there is a price to pay. Over years they commonly end in ® brosis, a form of paradoxical healing that accounts for the pelvic scarring, the joint and fascia deformities caused by serovars D± K, the rectal scarring that produces`pencil' stools in LGV, and contributes to blindness in trachoma, and no less the chronic, crippling and killing cardiovascular and pulmonary complications of C. pneumoniae infections 68, 69 . C. pneumoniae has been found to be frequently present in atheromatous plaques 70 , cases of degenerative aortic stenosis 71 , and infrarenal abdominal aortic aneurysms by nested PCR using primers against the MOMP gene 72 . All of those in whom this was detected were also positive by C. pneumoniae speci® c serology 73 .
The early recurrences common in all forms of chlamydial infection suggest that in terms of primary prevention, antibiotics have a limited potential. In terms of secondary prevention, that is their capacity to arrest the progress of late, chronic, crippling and killing manifestations, especially the late cardiovascular complications of C. pneumoniae infections, they may be even less effective 74± 77 . Even when such cases take antibiotics for a year, there is little or no apparent bene® t 78 . In vitro studies have determined the minimum inhibitory antibiotic concentrations 79 . These are exceeded in macrophages where concentrations are 2 to 10 times those found in plasma 80 . This is said to be advantageous in the eradication of chlamydia 81, 82 . Clinical experience to date does not bear this out.
It is becoming increasingly clear, that chlamydial infections, whether treated or not, are liable to move through 3 stages. The primary may be overt or asymptomatic, and be cured only clinically. The secondary state of latency may occasionally manifest its presence for recognizable or for unknown reasons. The tertiary stage is one of chronic, continuous disease activity. The similarity to syphilis will not escape genitourinary physicians, especially those who recollect Ehrlich's worries concerning the`horror autotoxicus' 83 .
FURTHER RESEARCH SUGGESTIONS FOR CONSIDERATION
In an editorial in 1994, Shahmanesh emphasized the damage resulting from late immunological responses 84 . He presented evidence of infection elsewhere than the genitourinary system and suggested that the monocyte/macrophage system could act as a reservoir. He made a plea for the pathophysiology of NGU to be addressed. It is hoped that our response will in some measure prove helpful. It could perhaps complement the plan for nationwide screening and treatment in the UK 85 and no less the plan of WHO to eliminate trachoma by the year 2020 86 . This last study will utilize a donation of azithromycin by P® zer valued at £41m.
As an intracellular component, azithromycin augments nature only modestly. When taken up by macrophages, it is`trapped' in their lysosomes and`delivered' on cell death at sites of infection. It would appear therefore the pharmaceutical industry believes that destruction of chlamydiae takes place mostly extracellularly. If this is so and in view of the lifespan of macrophages running to one month or more, further study of pharmacokinetics in terms of time/dosage relationships calls for detailed study. Meantime the need is to ensure that antibiotics ful® l their maximum potential in all stages of chlamydial infections. The ultimate aim should be an antibiotic which destroys chlamydiae whatever their intracellular state or stage of development. Clinical trials in genitourinary chlamydial infections similar to those conducted in C. pneumoniae late stage complications should be considered.
That a fresh infection may unmask latency calls for study. One starting point would be a follow-up of the observations of Kudesia et al. 87 . They examined 293 mid-stream urines submitted by general practitioners from males with suspected cystitis. Eighteen (6%) of the specimens were identi® ed as abacterial pyuria. C. trachomatis was found in all of them. We suggest that all specimens diagnosed as`bacterial' also be tested for coexisting chlamydial disease. From what has been said, ® nding occasional dual infections should not surprise.
What role is played by the envisaged chlamydia load is far from clear. An indicator of load is needed.
A more speculative thought concerns whether injections of IFN-g are capable of precipitating relapse just as superimposed infections appear to do? The molecular biochemistry of spontaneous recurrences of unknown cause also demands attention.
As regards the infecting organisms, it might be useful to correlate recent work regarding C. trachomatis serovars with emerging information concerning C. pneumoniae and the C. percorum of ruminants. Special attention might usefully be directed to antibody assays of IgA, IgM and IgG where latency is suspected but LCR or PCR tests prove negative 88 .
Immunologically orientated research at the cell mediated and molecular level should include a follow-up of the observation that some polymorphonuclear leucocytes produce a proteolytic enzyme with late chlamydial disease. Can this enzyme be isolated in bulk or manufactured? There are shades here of the frequently successful deployment of the proteolytic agent, potassium iodide, in cases of extensive dermal gummata and in the angina of vascular syphilis. The aim was prevention of rapid healing with contracting ® brosis resulting in`paradoxical healing'.
Of paramount importance is the need to demonstrate that chlamydiae continue to live in macrophages in the lymphatic system and elsewhere after nature or antibiotics deal effectively with early overt disease manifestations. Rather than wait for postmortem material, we suggest that enlarged pelvic and pre-aortic lymph nodes be identi® ed by magnetic resonance imaging. By needling such glands, the matter of parasitism could perhaps be settled. If, as suggested, parasitized macrophages circulate widely, why not aspirate or biopsy more available glands and the spleen as per Hurst and Shanahan (vide supra)?
Another suggestion needs the consideration of immunologists. Could the preparation of a monoclonal antibody, tagged with¯uorescent material and injected intravenously, be used to illuminate chlamydial antigenic material Ð detectable by computerized tomography or other technology?
How should the proposed research be organized? For the UK, 2 research teams each consisting of an immunologist, a chlamydiologist, a genitourinary physician, a gynaecologist and a cardiologist or chest physician would seem appropriate. The support of colleagues in other disciplines would be helpful. The total cost of genitourinary chlamydial infection and disease in the UK was estimated in 1996 at £50m per annum 89 . C. pneumoniae infections are likely to cost the country much more. Reducing costs of the ® rst, envisaged as a result of the nationwide screening programme, should offer a generous and encouraging government the opportunity to ® nance the suggested research. It could be a sound investment. Genitourinary medicine's record in health, and even wealth, creation has been exceptional in the century just ending.
One last thought: can the molecular messengers that prompt lymph nodes to despatch millions of phagocytes to distant peripheral sites be identi® ed, isolated in bulk and manufactured? If so, could they be introduced into the male urethra in suitable cases to reveal latency in lymph nodes?
But why go to such time-consuming and costly research when the same can be done by simply imitating nature? Just as telling would be the introduction into the urethras of volunteers, with a past history of chlamydial urethritis, cultured antibiotic-sensitive gonococci.
CODA
The historically minded will recognize that this review has been an attempt to imitate laboratory colleagues reaching an impasse in the last quarter of the 19th century. They then deployed what they called their minor speciality Ð semiology or semiotics. The pre® x is not that of Latin but the Greek semi' or`semion' meaning a sign (as in semaphore). In other words they recruited their clinical observations and experience to direct future research endeavours.
To our joint semiology we have added some hypothetical ideas, as story-tellers do, to make a narrative. We offer it for readers' criticism, improvement or replacement.
